Replies to post #322414 on Anavex Life Sciences Corp (AVXL)

[falconer66a]

No, 2022, next year.

The thing is the company has to be around in 2023.

Really? The company could go bust by the end of 2022? How so? They’ve got “Sufficient cash for >5 years to achieve key milestones,....” (p41, July corporate presentation PDF).

I’ll make a multi-thousand-dollar bet; with myself. By holding my AVXL position (no trading or sell-outs) until the end of 2023 I’m betting that in 2024 I’ll be way ahead; my long-term investment in Anavex Life Sciences Corp will be increasingly more valuable.

To lose this bet, the FDA (or Australian TGA) must reject the approval of blarcamesine for at least three diseases, Rett syndrome, Parkinson’s disease dementia, and Alzheimer’s. Approval of blarcamesine for any one of these will, by 2023, make Anavex a profitable, revenue-generating entity. The AVXL share price, necessarily, will reflect that. The probabilities of all three of the on-going clinical trials going bust are essentially non-existent. Way too much confirming clinical information. The unique MOA (mechanism of action) explains how this single molecule can facilitate such a multitude of favorable clinical outcomes. No other molecule can do this.

Think not, scrutinize the MOA info here, and then try to find anything like it by any other company:
http://www.anavex.com/wp-content/uploads/2021/07/Anavex-Presentation-July-2021.pdf

Anavex owns it; will provide its benefits to a) AVXL shareholders, b) millions of people across the globe suffering from CNS diseases, and c) government (tax-supported) health insurance and health care systems. Cumulatively, trillions of dollars in a decade.

[boi568]

The only way this company -- debt free with as much as five years of operating cash on hand -- isn't around in 2023 is if it is bought out before then for multiples of the current price.